Contribution of STAT3 and RAD23B in Primary Sézary Cells to Histone Deacetylase Inhibitor FK228 Resistance

Autor: Maria Demontis, Silvia A. Ferreira, Rosie M. Butler, Christine L. Jones, Tracey J. Mitchell, Isabella Tosi, Charlotte E. Flanagan, Robert C.T. McKenzie, Wesley J. Woollard, Sean Whittaker, Susan D. John
Jazyk: angličtina
Rok vydání: 2019
Předmět:
0301 basic medicine
CD4-Positive T-Lymphocytes
STAT3 Transcription Factor
Skin Neoplasms
DNA Copy Number Variations
medicine.drug_class
Primary Cell Culture
Apoptosis
Dermatology
Biochemistry
Polymorphism
Single Nucleotide

Romidepsin
03 medical and health sciences
0302 clinical medicine
Depsipeptides
medicine
Tumor Cells
Cultured

Humans
Sezary Syndrome
Phosphorylation
Molecular Biology
Vorinostat
Sezary Cell
Skin
Regulation of gene expression
Chemistry
Histone deacetylase inhibitor
Cutaneous T-cell lymphoma
Cell Biology
HDACi
STAT3
RAD23
Sezary Syndrome
CTCL
JAK
primary T cells

medicine.disease
Neoplastic Cells
Circulating

DNA-Binding Proteins
Gene Expression Regulation
Neoplastic

Histone Deacetylase Inhibitors
030104 developmental biology
Trichostatin A
DNA Repair Enzymes
Drug Resistance
Neoplasm

030220 oncology & carcinogenesis
Gene Knockdown Techniques
Cancer research
Tyrosine
Histone deacetylase
medicine.drug
Zdroj: Butler, R M, Mckenzie, R C, Jones, C L, Flanagan, C E, Woollard, W J, Demontis, M, Ferreira, S, Tosi, I, John, S, Whittaker, S J & Mitchell, T J 2019, ' Contribution of STAT3 and RAD23B in Primary Sézary Cells to Histone Deacetylase Inhibitor FK228 Resistance ', Journal of Investigative Dermatology, vol. 139, no. 9, pp. 1975-1984.e2 . https://doi.org/10.1016/j.jid.2019.03.1130
Popis: FK228 (romidepsin) and suberoylanilide hydroxamic acid (vorinostat) are histone deacetylase inhibitors (HDACi) approved by the US Food and Drug Administration for cutaneous T-cell lymphoma (CTCL), including the leukemic subtype Sezary syndrome. This study investigates RAD23B and STAT3 gene perturbations in a large cohort of primary Sezary cells and the effect of FK228 treatment on tyrosine phosphorylation of STAT3 (pYSTAT3) and RAD23B expression. We report RAD23B copy number variation in 10% (12/119, P ≤ 0.01) of SS patients, associated with reduced mRNA expression (P = 0.04). RAD23B knockdown in a CTCL cell line led to a reduction in FK228-induced apoptosis. Histone deacetylase inhibitor treatment significantly reduced pYSTAT3 in primary Sezary cells and was partially mediated by RAD23B. A distinct pattern of RAD23B-pYSTAT3 co-expression in primary Sezary cells was detected. Critically, Sezary cells harboring the common STAT3 Y640F variant were less sensitive to FK228-induced apoptosis and exogenous expression of STAT3 Y640F, and D661Y conferred partial resistance to STAT3 transcriptional inhibition by FK228 (P ≤ 0.0024). These findings suggest that RAD23B and STAT3 gene perturbations could reduce sensitivity to histone deacetylase inhibitors in SS patients.
Databáze: OpenAIRE